Laboratory StudyRegulation of glycogen synthase kinase-3 beta (GSK-3β) by the Akt pathway in gliomas
Introduction
Glioblastoma multiforme (GBM) represents the most lethal form of brain tumour which, despite intensive research, remains among the most deadly of all human cancers,1 with almost 100% mortality, irrespective of the interventions used.2, 3, 4 Patients treated with surgery, radiotherapy and chemotherapy survive an average of 14 months, with only 5% to 10% of patients surviving 2-year post-diagnosis.3, 5, 6 Gliomas are characterized by their diffuse and infiltrative nature7 which renders these cancers incurable by surgical intervention alone.8, 9, 10 Novel therapeutic treatments are required to improve patient outcomes. Glycogen synthase kinase-3 beta (GSK-3β) is a kinase at the crossroads of a plethora of signaling pathways that have been implicated in gliomagenesis and cancer in general. GSK-3β has roles in cell growth, proliferation, survival, cytoskeletal stability, microtubule dynamics, gene expression, neuronal polarization, nuclear export, differentiation, mood stabilization, neurodegeneration, apoptosis, but primarily for the process after which it was named, glycogen synthesis.[11, 12 GSK-3β’s input in both the Wnt signaling pathway and the phosphoinositide 3-kinase (PI3K)/Akt pathway (which are both commonly dysregulated in gliomagenesis) point to the possibility of this ubiquitously expressed kinase having a role in many biological factors regulated in gliomagenesis, including cell proliferation, apoptosis and tumour cell migration. The evidence that GSK-3β has a role in the myriad downstream effects of Akt suggests that selective inhibition of this kinase may permit the development of targeted molecular therapies for glioma. The present study investigated the effects of a non-specific, small-molecule inhibitor of GSK-3β, lithium chloride (LiCl), and a specific Akt inhibitor, AktX, on GSK-3β phosphorylation, proliferation, survival and morphology in adherent U87MG and U87MG.Δ2-7 cell lines, and one tumour stem cell-like cell line (TSC#004) grown as “neurospheres”.
Section snippets
Culture of glioma cells and neurospheres
Human glioblastoma cell lines U87MG and U87MG.Δ2-7 (containing the Δ2-7 epidermal growth factor receptor [EGFR] mutation, EGFRvIII)13 were cultured in Dulbecco’s Modified Eagle Medium (DMEM) + 5% fetal calf serum + penicillin/streptomycin (P/S) at 37 °C and 10% carbon dioxide (CO2) as described by Rubin et al.14 The human glioblastoma stem cell line TSC#004 was established in our laboratory directly from a freshly resected brain tumour. Cells were cultured in “neurosphere conditions” (DMEM/F12 + P/S
Drug treatment of adherent cells and neurospheres
Cells were treated with increasing concentrations of LiCl and AktX to determine if these compounds affected cell morphology. Treatment with LiCl (50 mM) and AktX (25 μM) resulted in an altered cell morphology for the U87MG and TSC#004 cells (Fig. 1). The effects of AktX were minimal at the lower concentration (10 μM) (Fig. 1E) with no clear morphological changes observed. High AktX concentrations of 25 μM (Fig. 1F) and 50 μM caused U87MG cells to lose their ability to adhere to the plate. Reduced
Discussion
Our study demonstrated that LiCl reduced the spreading of astrocytic processes in a dose-dependent manner, which is in contrast to the literature that implicates GSK-3β inhibition in axon and dendrite growth in neurons.19, 20, 21 As seen in Figs. 1A–C, increasing concentrations of LiCl resulted in U87MG cells withdrawing their processes and adopting a rounder conformation. Active GSK-3β has been shown to phosphorylate and inactivate both CRMP-2, a protein involved in determining neuronal
References (29)
- et al.
The EGFRvIII variant in glioblastoma multiforme
J Clin Neurosci
(2009) - et al.
Photodynamic therapy of cerebral glioma - a review. Part II - clinical studies
J Clin Neurosci
(2006) - et al.
Prognostic significance of Tks5 expression in gliomas
J Clin Neurosci
(2012) - et al.
Human brain glioma stem cells are more invasive than their differentiated progeny cells in vitro
J Clin Neurosci
(2012) - et al.
Targeting malignant glioma survival signalling to improve clinical outcomes
J Clin Neurosci
(2007) - et al.
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling
Prog Neurobiol
(2001) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes
Trends Pharmacol Sci
(2003)- et al.
Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes
J Biol Chem
(2000) - et al.
Phosphatidylinositol 3-kinase/Akt pathway targets acetylation of Smad3 through Smad3/CREB-binding protein interaction: contribution to transforming growth factor beta1-induced Epstein-Barr virus reactivation
J Biol Chem
(2009) - et al.
Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators
Cell
(2005)
GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity
Cell
Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway
J Biol Chem
Glycogen synthase kinase-3 and p38 MAPK are required for opioid-induced microglia apoptosis
Neuropharmacology
Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3
J Biol Chem
Cited by (52)
RRAGB-mediated suppression of PI3K/AKT exerts anti-cancer role in glioblastoma
2023, Biochemical and Biophysical Research CommunicationsGalectin-3 Mediates Tumor Progression in Astrocytoma by Regulating Glycogen Synthase Kinase-3β Activity
2023, Current Issues in Molecular BiologyThe Impediments of Cancer Stem Cells and An Exploration into the Nanomedical Solutions for Glioblastoma
2023, Anti-Cancer Agents in Medicinal ChemistryInhibition of FAM83D displays antitumor effects in glioblastoma via down-regulation of the AKT/Wnt/β-catenin pathway
2022, Environmental Toxicology